China's Livzon Pharmaceutical Group Inc. has made a bold move into the Vietnamese pharmaceutical market with a public bid offer valued at approximately VNĐ6.9 trillion (US$262.6 million) to acquire nearly 78% of Imexpharm Corporation's shares. This strategic acquisition, announced on January 19, 2026, underscores the intensifying cross-border investments in Asia's B2B pharmaceutical sector, particularly in contract manufacturing and production capabilities.

Imexpharm, a prominent Vietnamese pharmaceutical firm specializing in generic drug production, sterile injectables, and API formulations, has attracted this substantial offer from Lian SGP Holding Pte. Ltd., a wholly-owned subsidiary of Livzon. The bid targets 120 million shares, representing 77.94% of Imexpharm's charter capital and 77.96% of its total voting shares, at a premium price of VNĐ57,400 per share. This pricing reflects a robust valuation, especially as Imexpharm's shares closed at VNĐ53,700 on January 15, 2026, indicating strong market confidence in the deal's prospects[3].

For pharmaceutical executives and CRO/CMO leaders, this transaction highlights Livzon's intent to leverage Vietnam's growing role as a regional hub for pharmaceutical manufacturing. Vietnam's advantages include competitive labor costs, improving regulatory frameworks aligned with ASEAN standards, and strategic proximity to key supply chains in Southeast Asia. Imexpharm's facilities, equipped with advanced cleanroom solutions and validation-compliant production lines, position it ideally for scaling up contract services, including pharmaceutical formulations and packaging machinery integration.

Livzon, a major player in China's pharmaceutical industry with expertise in biotechnology and active pharmaceutical ingredients (APIs), has been eyeing expansion since May 2025. Initial plans targeted shares from major holders like SK Investment (47.69%), Binh Minh Kim Investment JSC (9.75%), and KBA Investment JSC (7.37%), initially covering 64.81% of equity. The expanded bid demonstrates heightened commitment amid Vietnam's pharma sector boom, driven by foreign direct investment in economic and regional development.

Imexpharm's financial performance bolsters the deal's appeal. Over the first 11 months of 2025, the company reported net revenue exceeding VNĐ2.2 trillion, a 14% year-on-year increase, with pre-tax profits surging 15% to VNĐ410 billion. This growth stems from enhanced production efficiency, investments in laboratory instrumentation, and pharmaceutical process machinery upgrades, aligning with B2B categories like pharmaceutical manufacturing equipment and quality assurance[3].

From a supply chain perspective, this acquisition could optimize pharmaceutical distribution and logistics across Asia. Livzon gains access to Imexpharm's established cold chain storage capabilities and export-oriented facilities, facilitating smoother integration into global pharma outsourcing networks. Regulatory teams will note Vietnam's progressing compliance with international standards, reducing barriers for cross-border pharmaceutical outsourcing.

Procurement professionals and technology vendors stand to benefit from potential partnerships in areas like pharmaceutical materials handling and excipients. The deal may spur joint ventures in R&D, focusing on Asian-specific formulations and natural extracts, while addressing environment recycle and water management in manufacturing.

Broader implications for Asian pharma include accelerated M&A activity, with Chinese firms like Livzon countering domestic oversupply by expanding abroad. This mirrors trends in contract research organizations and services, where ASEAN markets offer diversification from China-centric operations. Manufacturing managers can anticipate technology transfers in automation, robotics, and tableting/encapsulation processes.

Risk factors include regulatory approvals from Vietnamese authorities and potential scrutiny over foreign ownership in strategic sectors. However, the bid's structure, emphasizing public tender, ensures transparency and compliance with legislation and regulatory compliance standards.

Strategic insights for executives: Monitor similar deals in Thailand and Indonesia, where platforms like China-ASEAN Regional Medical Products Trading are fostering B2B ties. This acquisition exemplifies how partnerships drive innovation in pharmaceutical active ingredients and chemicals/intermediates supply chains[1][3].

In summary, Livzon's bid not only elevates Imexpharm's valuation but also reshapes competitive dynamics in Asian pharmaceutical outsourcing, promising enhanced capabilities in contract manufacturing, R&D, and supply chain solutions for the region's industry leaders.